Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Welcome to the 2018 Annual Medical Report. This year’s report — Go Further, Faster: Translating Science Into Practice — is a collection of 16 whitepapers by 29 diverse clinical thought leaders across the company, highlighting our proactive efforts to improve the care delivery system and address challenges and opportunities across the renal care spectrum. The report and its authors reflect the depth of our expertise, the breadth of our scientific and clinical explorations, and the strength of our commitment to continual learning for the benefit of the patients who entrust us with their care.
Franklin W. Maddux, MD, FACP
In a visionary outline of the vertically integrated Fresenius Medical Care North America ecosystem, Dr. Frank Maddux, FMCNA Chief Medical Officer and EVP for Clinical and Scientific Affairs, explores translating science into practice as a competitive advantage, and the quest to see emerging science as it evolves, to focus that science for the benefit of patients, and to harness the power of data-driven insights to reimagine the future of kidney care.
Murat Sor, MD
Warren S. Krackov, MD, MA, MS
Catherina Madormo, RN, BSN
The emerging field of regenerative medicine holds immediate and long-term promise for patients with end-stage renal disease (ESRD). In particular, bioengineered vessels have more immediate potential to address current shortcomings in vascular access, emerging as cost effective, reliable and safe alternatives to arteriovenous fistulas (AVFs), catheters and grafts.
Dinesh Chatoth, MD
Allan Collins, MD, FACP
Shorter, more frequent dialysis treatments can help improve cardiovascular complications and quality of life for end-stage renal disease (ESRD) patients. Given the prevalence of cardiovascular disease in patients with chronic kidney disease (CKD), with mortality rates 20 times higher than the general population, this has profound implications for patient care.